SCHEMBL1158992

SCHEMBL1158992

CC(C)(C)Nc1nc(Nc2cnccn2)cc2ccn(C[C@@H](O)c3ccccc3)c(=O)c12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 4/20 0.42
BTK Q06187 3/20 0.40
LYN P07948 1/20 0.40
SRC P12931 1/20 0.40
MAPKAPK2 P49137 1/20 0.38
GAA P10253 1/20 0.35
THRB P10828 1/20 0.35
HSD17B10 Q99714 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.32
RAB9A P51151 1/20 0.32
PRMT5 O14744 1/20 0.32
WDR77 Q9BQA1 1/20 0.32
GRM2 Q14416 1/20 0.32
ITGB3 P05106 1/20 0.31
ITGAV P06756 1/20 0.31
CYP2D6 P10635 1/20 0.31
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
TNF P01375 1/20 0.31
PKM P14618 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1158994 1.00 SYK (0.42) SYKBTKLYNSRCMAPKAPK2
SCHEMBL1158788 0.87 SYK (0.46) SYKBTKLYNSRC
SCHEMBL1159523 0.87 SYK (0.44) SYKBTKLYNSRCMAPKAPK2
SCHEMBL1158915 0.87 SYK (0.46) SYKBTKLYNSRC
SCHEMBL1159293 0.87 SYK (0.46) SYKBTKLYNSRC
SCHEMBL1159137 0.86 SYK (0.44) SYKBTKLYNSRCMAPKAPK2
SCHEMBL1159196 0.85 SYK (0.42) SYKBTKLYNSRCSMN1; SMN2
SCHEMBL1158553 0.84 SYK (0.44) SYKBTKLYNSRCMAPKAPK2
SCHEMBL12874414 0.83 SYK (0.43) SYKBTKLYNSRCMAPKAPK2
SCHEMBL12849008 0.83 SYK (0.44) SYKBTKLYNSRCMAPKAPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2459556-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2012-06-06 EP claimed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US claimed
WO-2011014515-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-02-03 WO claimed
EP-2459556-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2012-06-06 EP disclosed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US disclosed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US disclosed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US disclosed
WO-2011014515-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-02-03 WO disclosed
WO-2011014515-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS SYK, BTK, LYN SYK 1/4885BTK 2/4885LYN 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.